ThÃ©rÃ¨se Di Paolo-ChÃªnevert

List of Publications by Year
in descending order

205 papers	10,197 citations	20759 60 h-index	48187 88 g-index
207 all docs	207 docs citations	207 times ranked	6615 citing authors

#	Article	IF	Citations
1	Modulation of Brain Dopamine Transmission by Sex Steroids. Reviews in the Neurosciences, 1994, 5, 27-41.	1.4	325
2	Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiology of Disease, 2003, 14, 404-416.	2.1	208
3	Neuroprotective actions of sex steroids in Parkinsonâ€™s disease. Frontiers in Neuroendocrinology, 2009, 30, 142-157.	2.5	206
4	Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain, 2004, 127, 1075-1084.	3.7	189
5	17Î²-estradiol at a physiological dose acutely increases dopamine turnover in rat brain. European Journal of Pharmacology, 1985, 117, 197-203.	1.7	184
6	Neuroprotective properties of 17Î²-estradiol, progesterone, and raloxifene in MPTPC57Bl/6 mice. Synapse, 2001, 41, 131-138.	0.6	170
7	Defective dentate nucleus GABA receptors in essential tremor. Brain, 2012, 135, 105-116.	3.7	163
8	AFQ056 treatment of levodopaâ€induced dyskinesias: Results of 2 randomized controlled trials. Movement Disorders, 2011, 26, 1243-1250.	2.2	162
9	Ovarian steroids and selective estrogen receptor modulators activity on rat brain NMDA and AMPA receptors. Brain Research Reviews, 2001, 37, 153-161.	9.1	144
10	Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Progress in Neurobiology, 2007, 83, 293-309.	2.8	136
11	Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. NeuroReport, 2000, 11, 343-346.	0.6	133
12	Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17Î²-estradiol. Neuroscience Letters, 1988, 88, 113-118.	1.0	126
13	mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiology of Aging, 2008, 29, 1040-1051.	1.5	121
14	Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa-Induced Dyskinesias. Journal of Neuropathology and Experimental Neurology, 2002, 61, 186-196.	0.9	118
15	Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Research, 1995, 692, 269-272.	1.1	117
16	Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Molecular and Cellular Endocrinology, 2008, 290, 60-69.	1.6	117
17	Steroidsâ€Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience and Therapeutics, 2010, 16, e43-71.	1.9	117
18	Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. European Journal of Pharmacology, 1981, 73, 105-106.	1.7	116

#	Article	IF	Citations
19	Stereospecific prevention by 17?-estradiol of MPTP-induced dopamine depletion in mice. Synapse, 2000, 37, 245-251.	0.6	109
20	Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology, 2010, 58, 981-986.	2.0	108
21	Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy. Molecular Brain Research, 1997, 49, 55-62.	2.5	107
22	Elevated levels of Î”FosB and RGS9 in striatum in Parkinsonâ€™s disease. Biological Psychiatry, 2001, 50, 813-816.	0.7	107
23	Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. Journal of Psychiatry and Neuroscience, 2002, 27, 12-27.	1.4	107
24	Effect of prolactin and estradiol on rat striatal dopamine receptors. Life Sciences, 1982, 31, 2921-2929.	2.0	104
25	Associative and limbic regions of monkey striatum express high levels of dopamine D3receptors: effects of MPTP and dopamine agonist replacement therapies. European Journal of Neuroscience, 1998, 10, 2565-2573.	1.2	103
26	Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Movement Disorders, 2003, 18, 241-253.	2.2	102
27	Striatal D-2 dopamine agonist binding sites fluctuate during the rat estrous cycle. Life Sciences, 1988, 43, 665-672.	2.0	100
28	Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochemistry International, 2006, 48, 404-414.	1.9	98
29	Implication of the Phosphatidylinositol-3 Kinase/Protein Kinase B Signaling Pathway in the Neuroprotective Effect of Estradiol in the Striatum of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mice. Molecular Pharmacology, 2006, 69, 1492-1498.	1.0	97
30	Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Molecular Brain Research, 1997, 46, 343-346.	2.5	96
31	Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP-Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists. Journal of Neurochemistry, 1999, 72, 682-692.	2.1	96
32	Modulation by Estrogen-Receptor Directed Drugs of 5-Hydroxytryptamine-2A Receptors in Rat Brain. Neuropsychopharmacology, 2000, 23, 69-78.	2.8	96
33	ERÎ² mediates the estradiol increase of D2 receptors in rat striatum and nucleus accumbens. Neuropharmacology, 2006, 50, 451-457.	2.0	96
34	Docosahexaenoic acid reduces levodopaâ€induced dyskinesias in 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine monkeys. Annals of Neurology, 2006, 59, 282-288.	2.8	96
35	The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism and Related Disorders, 2011, 17, 270-276.	1.1	96
36	Effects of estrogens on the characteristics of [3H]spiroperidol and [3H]RU24213 binding in rat anterior pituitary gland and brain. Molecular and Cellular Endocrinology, 1979, 16, 99-112.	1.6	95

#	Article	IF	Citations
37	Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkinsonism and Related Disorders, 2009, 15, 445-452.	1.1	94
38	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism and Related Disorders, 2014, 20, 947-956.	1.1	93
39	Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders. Experimental Neurology, 2010, 225, 384-390.	2.0	89
40	Dehydroepiandrosterone (DHEA) such as 17?-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse, 2003, 47, 10-14.	0.6	88
41	Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 127-138.	2.5	85
42	Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiology of Aging, 2011, 32, 1286-1295.	1.5	85
43	Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. European Journal of Pharmacology, 1990, 178, 115-120.	1.7	83
44	Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ERÎ± agonist. Neuropharmacology, 2004, 47, 1180-1188.	2.0	83
45	Striatal D1 dopamine receptor density fluctuates during the rat estrous cycle. Neuroscience Letters, 1989, 98, 345-350.	1.0	82
46	Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends in Neurosciences, 2000, 23, S92-S100.	4.2	79
47	Gastrointestinal Dysfunctions in Parkinsonâ€™s Disease: Symptoms and Treatments. Parkinson's Disease, 2016, 2016, 1-23.	0.6	79
48	Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behavioural Brain Research, 2008, 186, 161-167.	1.2	77
49	Modeling dyskinesia in animal models of Parkinson disease. Experimental Neurology, 2014, 256, 105-116.	2.0	77
50	Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. European Journal of Pharmacology, 1988, 150, 59-66.	1.7	76
51	Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Research Bulletin, 1990, 25, 419-422.	1.4	76
52	Estrogenic Properties of Raloxifene, but Not Tamoxifen, on D₂ and D₃ Dopamine Receptors in the Rat Forebrain. Neuroendocrinology, 2002, 76, 214-222.	1.2	75
53	The modulation of brain dopamine and GABAA receptors by estradiol: A clue for CNS changes occurring at menopause. Cellular and Molecular Neurobiology, 1996, 16, 199-212.	1.7	74
54	Effects of Adrenalectomy and Glucocorticoids on Rat Brain Dopamine Receptors. Neuroendocrinology, 1992, 55, 468-476.	1.2	72

#	Article	IF	Citations
55	On the Hydrogen Bond Breaking Ability of Fluorocarbons Containing Higher Halogens. Canadian Journal of Chemistry, 1974, 52, 3612-3622.	0.6	71
56	Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research. Neuropharmacology, 2017, 115, 166-179.	2.0	70
57	A physiological dose of progesterone affects rat striatum biogenic amine metabolism. European Journal of Pharmacology, 1986, 125, 11-16.	1.7	69
58	Estrogen-like Activity of Tamoxifen and Raloxifene on NMDA Receptor Binding and Expression of its Subunits in Rat Brain. Neuropsychopharmacology, 2001, 25, 242-257.	2.8	68
59	Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism and Related Disorders, 2013, 19, 508-514.	1.1	68
60	Effect of estradiol and tamoxifen on brain membranes: investigation by infrared and fluorescence spectroscopy. Brain Research Bulletin, 1999, 49, 401-405.	1.4	62
61	Prevention of levodopa-induced dyskinesias by a selective NR1A/2BN-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin. Movement Disorders, 2006, 21, 9-17.	2.2	61
62	Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism and Related Disorders, 2004, 10, 297-304.	1.1	59
63	Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinsonâ€™s disease. Frontiers in Neuroendocrinology, 2012, 33, 169-178.	2.5	57
64	MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology, 2013, 66, 355-364.	2.0	57
65	Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiology of Aging, 2013, 34, 887-901.	1.5	53
66	Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology, 2013, 73, 216-231.	2.0	52
67	Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiology of Aging, 2014, 35, 2347-2356.	1.5	50
68	Levodopa-Induced Dyskinesia: Facts and Fancy. What Does the MPTP Monkey Model Tell Us?. Canadian Journal of Neurological Sciences, 1992, 19, 134-137.	0.3	49
69	Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture. Journal of Neurochemistry, 2002, 80, 307-316.	2.1	49
70	Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology, 2008, 54, 258-268.	2.0	49
71	Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. Neuropharmacology, 2019, 147, 37-54.	2.0	49
72	Hydrogen bond breaking potency of fluorocarbon anesthetics. Journal of Medicinal Chemistry, 1974, 17, 809-814.	2.9	48

#	Article	IF	Citations
73	Neuroprotection in Parkinsonian-treated mice via estrogen receptor Î± activation requires G protein-coupled estrogen receptor 1. Neuropharmacology, 2015, 95, 343-352.	2.0	48
74	Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABAA/benzodiazepine receptor complex and GABA content. Neurochemistry International, 1999, 35, 81-91.	1.9	47
75	Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias. European Journal of Neuroscience, 2011, 33, 1823-1831.	1.2	47
76	Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology, 2007, 52, 1509-1520.	2.0	45
77	Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience, 2010, 167, 1160-1167.	1.1	45
78	GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease. Neurobiology of Disease, 2015, 82, 99-113.	2.1	45
79	Effect of Neonatal Thyroid Deficiency on the Catecholamine, Substance P, and Thyrotropin-Releasing Hormone Contents of Discrete Rat Brain Nuclei. Endocrinology, 1981, 108, 2039-2045.	1.4	44
80	Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. Biochemical Pharmacology, 1993, 45, 723-733.	2.0	44
81	Sex differences in methamphetamine toxicity in mice: Effect on brain dopamine signaling pathways. Psychoneuroendocrinology, 2011, 36, 955-969.	1.3	44
82	An m<scp>G</scp>lu4â€<scp>P</scp>ositive <scp>A</scp>llosteric <scp>M</scp>odulator <scp>A</scp>lleviates <scp>P</scp>arkinsonism in <scp>P</scp>rimates. Movement Disorders, 2018, 33, 1619-1631.	2.2	44
83	Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias. Journal of Molecular Neuroscience, 2009, 38, 128-142.	1.1	43
84	Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Movement Disorders, 1993, 8, 144-150.	2.2	42
85	Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Molecular Brain Research, 2003, 112, 82-89.	2.5	42
86	Effect of neonatal hypothyroidism on the serotonin system of the rat brain. Brain Research, 1984, 292, 99-108.	1.1	41
87	Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochemical Pharmacology, 1997, 54, 391-397.	2.0	41
88	Levodopa response motor complicationsâ€”GABA receptors and preproenkephalin expression in human brain. Parkinsonism and Related Disorders, 2002, 8, 449-454.	1.1	41
89	Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors. Synapse, 2006, 60, 239-250.	0.6	41
90	Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 446-454.	2.5	41

#	Article	IF	Citations
91	AQW051, a novel and selective nicotinic acetylcholine receptor Î±7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism and Related Disorders, 2014, 20, 1119-1123.	1.1	41
92	Chronic estradiol treatment increases ovariectomized rat striatal D-1 dopamine receptors. Life Sciences, 1989, 45, 1813-1820.	2.0	40
93	Nur77 Gene Knockout Alters Dopamine Neuron Biochemical Activity and Dopamine Turnover. Biological Psychiatry, 2006, 60, 538-547.	0.7	40
94	Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides. Neuropharmacology, 2010, 58, 286-296.	2.0	40
95	Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. PLoS ONE, 2016, 11, e0151020.	1.1	40
96	Molecular Connectivity in Quantitative Structure-Activity Relationship Study of Anesthetic and Toxic Activity of Aliphatic Hydrocarbons, Ethers, and Ketones. Journal of Pharmaceutical Sciences, 1978, 67, 566-568.	1.6	39
97	Metabotropic Glutamate Receptors for Parkinson's Disease Therapy. Parkinson's Disease, 2013, 2013, 1-11.	0.6	38
98	Perturbation of Rat Brain Serotonergic Systems Results in an Inverse Relation Between Substance P and Serotonin Concentrations Measured in Discrete Nuclei. Journal of Neurochemistry, 1983, 41, 834-840.	2.1	37
99	A physiological dose of estradiol with progesterone affects striatum biogenic amines. Canadian Journal of Physiology and Pharmacology, 1990, 68, 1520-1526.	0.7	37
100	Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism and Related Disorders, 2004, 10, 221-226.	1.1	37
101	Effect of lâ€Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. Journal of Neurochemistry, 2010, 113, 715-724.	2.1	37
102	Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinsonâ€™s disease. Neuropharmacology, 2011, 61, 583-591.	2.0	37
103	Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2016, 67, 79-88.	2.9	36
104	125I-CGP 64213 Binding to GABAB Receptors in the Brain of Monkeys: Effect of MPTP and Dopaminomimetic Treatments. Experimental Neurology, 2000, 163, 191-199.	2.0	35
105	Oestradiol Modulation of Serotonin Reuptake Transporter and Serotonin Metabolism in the Brain of Monkeys. Journal of Neuroendocrinology, 2013, 25, 560-569.	1.2	34
106	Fluorocarbon anaesthetics break hydrogen bonds. Nature, 1974, 252, 471-472.	13.7	33
107	Progesterone releases dopamine in male and female rat striatum: A behavioral and microdialysis study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 491-497.	2.5	33
108	Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 473-480.	2.5	32

#	Article	IF	Citations
109	Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens. Psychoneuroendocrinology, 2005, 30, 251-260.	1.3	32
110	Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid. Neurobiology of Disease, 2009, 36, 213-222.	2.1	32
111	Effect of the rat estrous cycle at ovariectomy on striatal D-1 dopamine receptors. Brain Research Bulletin, 1990, 24, 281-284.	1.4	31
112	Effect of MPTP-induced denervation on basal ganglia GABABreceptors: Correlation with dopamine concentrations and dopamine transporter. Synapse, 2001, 40, 225-234.	0.6	31
113	Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Frontiers in Neurology, 2014, 5, 144.	1.1	31
114	Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice. Neuroendocrinology, 2016, 103, 300-314.	1.2	31
115	Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. Journal of Psychiatry and Neuroscience, 2005, 30, 110-7.	1.4	31
116	Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. , 1999, 32, 153-164.		30
117	The 5Î±-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 2015, 97, 86-94.	2.0	30
118	Differential Protective Properties of Estradiol and Tamoxifen against Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity in Mice. Neuroendocrinology, 2005, 82, 111-120.	1.2	29
119	Subthalamotomy in the treatment of Parkinson's disease: clinical aspects and mechanisms of action. Journal of Neurosurgery, 2014, 120, 140-151.	0.9	29
120	Non-human primate models of PD to test novel therapies. Journal of Neural Transmission, 2018, 125, 291-324.	1.4	29
121	Effect of estradiol and haloperidol on hypophysectomized rat brain dopamine receptors. Psychoneuroendocrinology, 1984, 9, 399-404.	1.3	28
122	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Movement Disorders, 2016, 31, 1049-1054.	2.2	28
123	DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys. Neurobiology of Aging, 2006, 27, 1684-1693.	1.5	27
124	Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients. Journal of Neuropathology and Experimental Neurology, 2009, 68, 374-382.	0.9	27
125	Male/female differences in neuroprotection and neuromodulation of brain dopamine. Frontiers in Endocrinology, 2011, 2, 35.	1.5	26
126	Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Neuropharmacology, 2014, 79, 688-706.	2.0	26

#	Article	IF	Citations
127	Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 90, 81-96.	2.0	26
128	Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys. Psychoneuroendocrinology, 1984, 9, 375-379.	1.3	25
129	Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors. NeuroReport, 2001, 12, 535-539.	0.6	25
130	Dopamine Transporter as a Marker of Neuroprotection in Methamphetamine-Lesioned Mice Treated Acutely with Estradiol. Neuroendocrinology, 2004, 79, 296-304.	1.2	25
131	Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochemical Pharmacology, 2007, 74, 1413-1423.	2.0	25
132	l-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. Journal of Chemical Neuroanatomy, 2008, 35, 77-84.	1.0	25
133	Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys. Journal of Neuroscience Research, 2009, 87, 1634-1644.	1.3	25
134	Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy. Neuropharmacology, 2011, 60, 642-652.	2.0	23
135	Effects of progesterone administered after MPTP on dopaminergic neurons of male mice. Neuropharmacology, 2017, 117, 209-218.	2.0	23
136	Molecular Connectivity Study of Halocarbon Anesthetics. Journal of Pharmaceutical Sciences, 1979, 68, 39-42.	1.6	22
137	Prolactin and estradiol increase striatal dopamine receptor density in intact, castrated and hypophysectomized rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1982, 6, 377-382.	2.5	22
138	Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys. Experimental Neurology, 1983, 82, 172-182.	2.0	22
139	Estradiol and Dehydroepiandrosterone Potentiate Levodopa-Induced Locomotor Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkeys. Endocrine, 2003, 21, 97-102.	2.2	22
140	Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease. Neurobiology of Aging, 2016, 48, 61-71.	1.5	22
141	Effects of ovariectomy and estradiol on acoustic startle responses in rats. Pharmacology Biochemistry and Behavior, 2002, 74, 103-109.	1.3	21
142	Interaction of dehydroepiandrosterone with phospholipid membranes:. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1368, 321-328.	1.4	20
143	Effect of a chronic treatment with 17Î²-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology, 2012, 37, 280-291.	1.3	20
144	Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Behavioural Brain Research, 2015, 286, 328-337.	1.2	20

#	Article	IF	Citations
145	Distribution of Dopamine in 35 Subregions of the Rat Caudate-Putamen: A High Performance Liquid Chromatography with Electrochemical Detection Analysis. Canadian Journal of Neurological Sciences, 1982, 9, 421-427.	0.3	19
146	Chronic estradiol treatment increases anterior pituitary but not striatal D2 dopamine receptor mRNA levels in rats. Neuroscience Letters, 1992, 140, 5-8.	1.0	19
147	Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958. European Journal of Pharmacology, 1999, 378, 259-263.	1.7	19
148	Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochemical Pharmacology, 2013, 86, 970-978.	2.0	19
149	Chronic CY 208â€“243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors. Neuroscience Letters, 1993, 163, 31-35.	1.0	18
150	Effect of adding the D-1 agonist CY 208â€“243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 667-676.	2.5	18
151	Structure-Activity Relationships of Anesthetic Ethers Using Molecular Connectivity. Journal of Pharmaceutical Sciences, 1978, 67, 564-566.	1.6	17
152	Determination of 5-hydroxytryptophan, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in 20 rat brain nuclei using liquid chromatography with electrochemical detection. Canadian Journal of Physiology and Pharmacology, 1983, 61, 530-534.	0.7	17
153	Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain. Neurochemistry International, 2012, 61, 1160-1171.	1.9	17
154	Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways. Neuropharmacology, 2012, 62, 2363-2372.	2.0	17
155	mGlu5, Dopamine D₂and Adenosine A_{2A}Receptors in L-DOPA-induced Dyskinesias. Current Neuropharmacology, 2016, 14, 481-493.	1.4	17
156	Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 607-617.	2.5	16
157	Naltrexone in the short-term decreases antiparkinsonian response to -Dopa and in the long-term increases dyskinesias in drug-naÃ¯ve parkinsonian monkeys. Neuropharmacology, 2005, 49, 165-173.	2.0	16
158	Effect of the 5Î±-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 242-256.	1.2	16
159	Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys. Frontiers in Neuroanatomy, 2018, 12, 38.	0.9	16
160	Interaction of Adenosine Receptors with Other Receptors from Therapeutic Perspective in Parkinson's Disease. International Review of Neurobiology, 2014, 119, 151-167.	0.9	15
161	The number of striatal cholinergic interneurons expressing calretinin is increased in parkinsonian monkeys. Neurobiology of Disease, 2016, 95, 46-53.	2.1	15
162	Steroid 5Î±-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors. Psychoneuroendocrinology, 2018, 91, 95-104.	1.3	15

#	Article	IF	Citations
163	Effect of dehydroepiandrosterone and its sulfate and fatty acid ester derivatives on rat brain membranes. Steroids, 1999, 64, 796-803.	0.8	14
164	Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol. Journal of Neuroscience Research, 2005, 80, 138-144.	1.3	14
165	Selective estrogen receptor-Î± but not -Î² agonist treatment modulates brain Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Journal of Neuroscience Research, 2006, 84, 1076-1084.	1.3	14
166	Dopamine receptors in rat pituitary and estradiol-induced pituitary tumor: Effect of chronic treatment with bromocriptine. Biochemical and Biophysical Research Communications, 1984, 123, 312-316.	1.0	13
167	Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems. Biochemical Pharmacology, 2009, 78, 1401-1411.	2.0	13
168	Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications. Neuropharmacology, 2015, 99, 356-368.	2.0	13
169	Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor. Brain Research, 2019, 1725, 146460.	1.1	13
170	Central 5-Hydroxytryptamine-2A Receptor Expression in Transgenic Mice Bearing a Glucocorticoid Receptor Antisense. Neuroendocrinology, 2001, 73, 37-45.	1.2	12
171	Functional neurochemistry of the basal ganglia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 19-66.	1.0	12
172	Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice. Brain Research, 2017, 1674, 70-76.	1.1	12
173	Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice. Neuropharmacology, 2021, 201, 108784.	2.0	12
174	Physiological doses of estradiol can increase lingual dyskinesia and cerebrospinal fluid homovanillic acid in monkeys. Neuroscience Letters, 1985, 58, 327-331.	1.0	11
175	Normalization of GABA_A receptor specific binding in the substantia nigra reticulata and the prevention of <scp>L</scp>â€dopaâ€induced dyskinesias in MPTP parkinsonian monkeys. Synapse, 2008, 62, 101-109.	0.6	11
176	Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 170-177.	2.5	11
177	BDNF levels are not related with levodopaâ€induced dyskinesias in MPTP monkeys. Movement Disorders, 2010, 25, 116-121.	2.2	10
178	Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 27-38.	2.5	10
179	Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease. Journal of Neuroendocrinology, 2020, 32, e12782.	1.2	10
180	Implication of the serotoninergic system in the decreased ACTH response to stress after lesion of the amygdaloid central nucleus. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 665-669.	2.5	9

#	Article	IF	Citations
181	Acute effect of 17Î²-estradiol and lithium on ovariectomized rat brain biogenic amines metabolism. Journal of Psychiatric Research, 1996, 30, 95-107.	1.5	9
182	Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy. Journal of Neurosurgery, 2013, 118, 180-191.	0.9	9
183	Brain Î±7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. Biochemical Pharmacology, 2016, 109, 62-69.	2.0	8
184	Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters. Neuropharmacology, 2018, 133, 289-306.	2.0	8
185	Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys. Cells, 2022, 11, 691.	1.8	8
186	Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinsonâ€™s disease. Journal of Steroid Biochemistry and Molecular Biology, 2016, 161, 84-91.	1.2	7
187	Retinal dopamine sensitivity to MPP+ toxicity: electrophysiological and biochemical evaluation. Neuroscience Letters, 1989, 107, 19-25.	1.0	6
188	Modulation of dopamine receptor agonist binding sites by cations and estradiol in intact pituitary and 7315a tumors. Biochemical Pharmacology, 1991, 42, 2163-2169.	2.0	6
189	The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys. Behavioural Brain Research, 2018, 337, 183-185.	1.2	6
190	Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models. Androgens: Clinical Research and Therapeutics, 2021, 2, 294-303.	0.2	6
191	Effects of a luteinizing hormone-releasing hormone analog on the growth of estrogen-induced prolactin-secreting rat pituitary tumors and its influence on their dopamine receptors. European Journal of Pharmacology, 1984, 102, 383-384.	1.7	5
192	Natural Phytoestrogens. , 2018, , 9-61.		5
193	Estradiol and guanine nucleotide modulation of dopamine receptor agonist and antagonist binding sites in 7315a pituitary tumors. Biochemical Pharmacology, 1988, 37, 2373-2379.	2.0	4
194	Neuroactive steroids and Parkinson's disease. Current Opinion in Endocrine and Metabolic Research, 2022, 22, 100312.	0.6	4
195	Guanine nucleotide regulation of dopamine receptor agonist affinity states in rat estradiol-induced pituitary tumors. Life Sciences, 1987, 41, 1149-1153.	2.0	3
196	Sodium and guanine nucleotide regulation of dopamine receptor agonist and antagonist binding sites in MtTW15 pituitary tumors. Canadian Journal of Physiology and Pharmacology, 1988, 66, 246-249.	0.7	3
197	Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: Electrophysiological and biochemical evidence. Experimental Eye Research, 1989, 49, 543-552.	1.2	3
198	Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. Journal of Neurosurgery, 2015, 123, 1383-1393.	0.9	3

#	Article	IF	Citations
199	Differential contribution of estrogen receptors to the intestinal therapeutic effects of 17Î²-estradiol in a murine model of Parkinsonâ€™s disease. Brain Research Bulletin, 2022, 187, 85-97.	1.4	3
200	Modulation of dopamine receptors by cations in 7315a, MtTW15 and estradiol-induced pituitary tumors. Biochemical Pharmacology, 1990, 40, 1373-1380.	2.0	2
201	Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys. Experimental Neurology, 2014, 261, 816-825.	2.0	2
202	Liquid chromatography coupled to tandem mass spectrometry methods for the selective and sensitive determination of 24Sâ€hydroxycholesterol, its sulfate, and/or glucuronide conjugates in plasma. Journal of Mass Spectrometry, 2022, 57, e4827.	0.7	2
203	Dopamine Receptors and Levodopa-Induced Dyskinesia. , 2014, , 171-197.		0
204	Neuroleptic-Like Activity of Estrogens. , 1985, , 237-242.		0
205	mGlu5 Receptors in Parkinsonâ€™s Disease and MPTP-Lesioned Monkeys: Behavior and Brain Molecular Correlates. Receptors, 2017, , 183-205.	0.2	0